




RealRate

MEDICINAL PRODUCTS 2013

Innospec INC
Rank 14 of 44





MEDICINAL PRODUCTS 2013

Innospec INC
Rank 14 of 44



The relative strengths and weaknesses of Innospec INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innospec INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Innospec INC is the variable Other Expenses, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 74% points above the market average of 158%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	296,600	Liabilities	147,300
Assets, Non-Current	1,400	Assets	579,400
General and Administrative Expense	117,100	Expenses	652,900
Goodwill	217,600	Revenues	776,400
Liabilities, Current	147,300	Stockholders Equity	432,100
Liabilities, Non-Current	0	Net Income	122,100
Other Assets	14,000	Comprehensive Net Income	122,100
Other Compr. Net Income	0	BaseVar	1,078,700
Other Expenses	516,200	ECR before LimitedLiability	197%
Other Liabilities	0	Economic Capital Ratio	232%
Other Net Income	-1,400		
Other Revenues	776,400		
Property, Plant and Equipment, Net	49,800		
Research and Development	19,600		